Results 91 to 100 of about 779,609 (165)

Switching from infliximab to biosimilar in inflammatory bowel disease: overview of the literature and perspective

open access: yesTherapeutic Advances in Gastroenterology, 2019
Background: Biological therapy has revolutionized the treatment of inflammatory bowel disease (IBD). After the expiration of patents for biological innovator products, development of biosimilars increased. CT-P13 was the first biosimilar approved for the
Ágnes Milassin   +2 more
doaj   +1 more source

Är det säkert att byta från originalläkemedlet för inflixmab, Remicade®, till CT-P13 och är CT-P13 ekvivalent med Remicade® med avseende på effekt, säkerhet, immunogenicitet och farmakokinetik?

open access: yes, 2016
Biologiska läkemedel är effektiva vid flera sjukdomstillstånd men de är mycket dyra. År 2006 godkände den Europeiska läkemedelsmyndigheten försäljning av biosimilarer.
Adler, Anna
core   +3 more sources

Analysis of real-world treatment patterns in a matched rheumatology population that continued innovator infliximab therapy or switched to biosimilar infliximab

open access: yesBiologics: Targets & Therapy, 2018
Yusuf Yazici,1 Lin Xie,2 Adesuwa Ogbomo,2 Lorie A Ellis,3 Kavitha Goyal,4 Amanda Teeple,5 Ismail Simsek6 1Rheumatology, New York University, School of Medicine, New York, NY, USA; 2Health Economics and Outcomes Research, STATinMED Research, Ann Arbor, MI,
Yazici Y   +6 more
doaj  

A critical review of the United States regulatory pathways for determining the equivalence of efficacy between CT-P13 and original infliximab (Remicade®)

open access: yesDrug Design, Development and Therapy, 2020
Soohyun Kim, 1, 2,* Siun Kim, 1, 2,* Howard Lee 1– 4 1Department of Transdisciplinary Studies, Graduate School of Convergence Science and Technology, Seoul National University, Seoul, Korea; 2Center for Convergence Approaches in Drug Development,
Kim S, Kim S, Lee H
doaj  

Efficacy and safety of biosimilar IFX (CT-P13) and adalimumab in patients with active fistulizing perianal Crohn’s disease naďve to anti-TNF therapy: preliminary results from the POLIBD study [PDF]

open access: yes, 2019
Introduction. The development of perianal fistulas are a risk factor in colonic and rectal disease. Perianal CD treatment requires a combination of surgical and therapeutic treatments aimed to prevent septic complications, reduce fistula discharge and ...
Rafał Filip   +7 more
core   +2 more sources

Update on biosimilars in inflammatory bowel disease: Position and recommendations in Mexico

open access: yesRevista de Gastroenterología de México (English Edition), 2018
The biotechnology-derived medicines known as biosimilars are defined as non-originator treatments that have demonstrated quality, efficacy, and safety comparable to the reference biologic drug.
A. Mayoral-Zavala   +9 more
doaj   +1 more source

Actualización sobre los medicamentos biocomparables en la enfermedad inflamatoria intestinal: posición y recomendación en México

open access: yesRevista de Gastroenterología de México, 2018
Resumen: Los medicamentos biotecnológicos biocomparables son definidos como tratamientos no innovadores que han demostrado calidad, eficacia y seguridad comparable al medicamento de referencia.
A. Mayoral-Zavala   +9 more
doaj   +1 more source

Does the introduction of an infliximab biosimilar always result in savings for hospitals? A descriptive study using real-world data

open access: yesHealth Economics Review
Background Biosimilars are biologic drugs that have the potential to increase the efficiency of healthcare spending and curb drug-related cost increases.
Marko Krstic   +3 more
doaj   +1 more source

A Comparison of Intravenous Infliximab Versus Subcutaneous Infliximab on Remission Rates, Safety, Costs, Patient Preferences in Patients With Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis

open access: yesGastro Hep Advances
Background and Aims: Infliximab, widely used as a mainstay treatment of inflammatory bowel disease (IBD), is traditionally administered intravenously. The subcutaneous (SC) formulation appears to offer a more convenient route of administration. This is a
Alejandro Nieto Dominguez   +6 more
doaj   +1 more source

A review of the literature analyzing benefits and concerns of infliximab biosimilar CT-P13 for the treatment of rheumatologic diseases: focus on interchangeability

open access: yesDrug Design, Development and Therapy, 2017
Andrea Becciolini,1 Maria Gabriella Raimondo,2 Chiara Crotti,2 Elena Agape,2 Martina Biggioggero,2 Ennio Giulio Favalli1 1Department of Rheumatology, 2Department of Clinical Sciences and Health Community, University of Milan, Division of Rheumatology ...
Becciolini A   +5 more
doaj  

Home - About - Disclaimer - Privacy